Medical Procurement Organization Reviews Soha Pharmaceutical Performance, Stresses Profitability

According to the Public Relations and International Affairs Unit of the Medical Procurement Organization, the performance review meeting for Saha Pharmaceutical Company was held on Monday, January 25, 2026 (5 Bahman 1404) in the conference hall of the Medical Procurement Organization. The session was chaired by Dr. Shanehsaz, Managing Director of the Medical Procurement Organization, with the attendance of senior headquarters officials.

Dr. Mirhosseiniyan, Managing Director of Soha Pharmaceutical Company, along with several senior managers of the company, also attended the meeting. During the session, the company's management presented an analytical report on its current status, key performance indicators, and financial trends, and outlined its main upcoming programs and priorities. The meeting was convened in line with the directives of the President of the Iranian Red Crescent Society, aiming to ensure continuous performance evaluation of affiliated companies, strengthen management oversight mechanisms, and verify alignment of operational activities with approved macro policies and strategic orientations.

Given the recent appointment of new members to the company's Board of Directors, the meeting underscored the necessity of increasing Soha Pharmaceutical's market share and influence within the national pharmaceutical sector, enhancing operational productivity, and fulfilling its primary mission of supplying essential medicines to patients while alleviating their treatment concerns. In this context, the importance of steering the company toward sustainable profitability and adopting financially driven decision-making was highlighted.

Another key focus of the session was reinforcing corporate governance and expediting procurement and transaction processes while fully adhering to applicable laws and regulations. Accordingly, the company was directed— in collaboration with its Board of Directors—to update its financial and transactional bylaws, secure internal approval, and subsequently submit them to the Medical Procurement Organization (as holding entity) for final review.

The meeting also emphasized activating internal audit functions and the Audit Committee more effectively. It was resolved that issues raised in the independent auditor's report must be addressed with sufficient, precise, and defensible documentation.

Addressing rising overhead costs, energy expenses, and exchange rate fluctuations—and their impact on gross profit—participants discussed strategies to reduce total production costs and enhance profitability. The company was also instructed to report its accounts receivable cycle and financial turnover period to the Medical Procurement Organization to support informed managerial decision-making.

Furthermore, the role of the Product Selection Committee and the Research and Development (R&D) unit was underscored. It was resolved that, considering market supply and demand dynamics, priority should be given to products requiring lower raw material inputs and offering higher added value—particularly high-tech medicines and other pharmaceuticals with reduced dependency on imported raw materials.

Finally, the submission of a comprehensive business plan and profitability roadmap for Soha Pharmaceutical Company to the Medical Procurement Organization was emphasized as a fundamental requirement for future strategic planning.